Nelfinavir: Difference between revisions
Jump to navigation
Jump to search
imported>David E. Volk No edit summary |
imported>David E. Volk m (ditto) |
||
Line 3: | Line 3: | ||
{{Chem infobox | {{Chem infobox | ||
|align=right | |align=right | ||
|image=[[Image:Nelfinavir structure.jpg| | |image=[[Image:Nelfinavir structure.jpg|center|thumb|250px]] | ||
|width=250px | |width=250px | ||
|molname=nelfinavir | |molname=nelfinavir |
Revision as of 15:45, 26 March 2008
| |||||||
nelfinavir | |||||||
| |||||||
Uses: | HIV | ||||||
Properties: | protease inhibitor | ||||||
Hazards: | see drug interactions | ||||||
|
Nelfinavir, sometimes abbreviated as NFV or NLF and sold under the brand name Viracept® is a protease inhibitor used to treat HIV/AIDS. Nelfinavir binds to and inhibits the HIV-1 viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in non-infectious, immature viral particles. Its short half-life (3.5-5 hr) and the lack of activity of it major metabolites means that nelfinavir must be taken every 4-5 hours. It most often used in combination with two or more anti-HIV drugs.
Chemistry
Its chemical name is (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino] -4-phenylsulfanylbutyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide, and its chemical formula is C32H45N3O4S.
External Links
- Nelfinavir - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
- Template:MedMaster
- Template:DrugBank